Genomic architecture of autism from comprehensive whole-genome sequence annotation
…, A Rutherford, V Aguda, B Apresto, N Chen, S Desai… - Cell, 2022 - cell.com
Fully understanding autism spectrum disorder (ASD) genetics requires whole-genome
sequencing (WGS). We present the latest release of the Autism Speaks MSSNG resource, which …
sequencing (WGS). We present the latest release of the Autism Speaks MSSNG resource, which …
[HTML][HTML] Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh
…, NC Saha, A Kabir, A Cravioto, SN Desai… - … England Journal of …, 2016 - Mass Medical Soc
Background A single-dose regimen of the current killed oral cholera vaccines that have been
prequalified by the World Health Organization would make them more attractive for use …
prequalified by the World Health Organization would make them more attractive for use …
[HTML][HTML] Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: a systematic literature review
V Mogasale, SN Desai, VV Mogasale, JK Park… - PLoS …, 2014 - journals.plos.org
Background Typhoid fever remains a major health problem in the developing world. Intestinal
perforation is a lethal complication and continues to occur in impoverished areas despite …
perforation is a lethal complication and continues to occur in impoverished areas despite …
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non–bile acid FXR agonist tropifexor (LJN452) in healthy volunteers
MK Badman, J Chen, S Desai, S Vaidya… - … in drug development, 2020 - Wiley Online Library
Tropifexor (LJN452) is a potent, orally available, non–bile acid farnesoid X receptor agonist
under clinical development for chronic liver diseases. Here, we present results from a first‐in‐…
under clinical development for chronic liver diseases. Here, we present results from a first‐in‐…
Oral vaccines against cholera
S Shin, SN Desai, BK Sah… - Clinical infectious …, 2011 - academic.oup.com
The current seventh pandemic of cholera, caused by serogroup O1, El Tor biotype, has now
involved almost the entire developing world. The ongoing dynamic epidemiology of cholera, …
involved almost the entire developing world. The ongoing dynamic epidemiology of cholera, …
A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines
…, JS Yeam, JS Yang, JY Park, DR Kim, SN Desai… - Vaccine, 2015 - Elsevier
Background Currently, there are two oral cholera vaccines (OCV) that are prequalified by
the World Health Organization. Both (Dukoral and Shanchol) have been proven to be safe, …
the World Health Organization. Both (Dukoral and Shanchol) have been proven to be safe, …
[HTML][HTML] Medical management of oral lichen planus: A systematic review
SS Suresh, K Chokshi, S Desai, R Malu… - Journal of Clinical and …, 2016 - ncbi.nlm.nih.gov
Aim The aim was to assess the efficacy of any form of intervention used to medically
manage OLP. Materials and Methods We searched and analysed the following databases (from …
manage OLP. Materials and Methods We searched and analysed the following databases (from …
[HTML][HTML] A second affordable oral cholera vaccine: implications for the global vaccine stockpile
SN Desai, L Pezzoli, S Martin, A Costa… - The Lancet Global …, 2016 - thelancet.com
On Dec 23, 2015, WHO prequalified a second affordable oral cholera vaccine (OCV),
Euvichol (Eubiologics, South Korea), which is expected to double current global OCV …
Euvichol (Eubiologics, South Korea), which is expected to double current global OCV …
Domain topology of nucleoporin Nup98 within the nuclear pore complex
G Chatel, SH Desai, AL Mattheyses, MA Powers… - Journal of structural …, 2012 - Elsevier
Nuclear pore complexes (NPCs) facilitate selective transport of macromolecules across the
nuclear envelope in interphase eukaryotic cells. NPCs are composed of roughly 30 different …
nuclear envelope in interphase eukaryotic cells. NPCs are composed of roughly 30 different …
[HTML][HTML] Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings
A Hsiao, SN Desai, V Mogasale, JL Excler… - Bulletin of the World …, 2017 - ncbi.nlm.nih.gov
The World Health Organization (WHO) estimates that there are 1.3 to 4.0 million cholera
cases annually and that 21 000 to 143 000 of them result in death. 1 Additionally, in …
cases annually and that 21 000 to 143 000 of them result in death. 1 Additionally, in …
